Capitalize on the Increased Resolution of Experimental Structural Techniques & Evolving Predictive AI Model Accuracy to Determine 3D Structures of Pharmacologically Relevant Targets, Enabling Design of More Potent, Selective, & Tolerable Drug Candidates
Following the success of the Structure-Based Drug Design Summit in Boston, we were delighted to bring this forum to the West Coast, uniting biopharma leaders who are driving the next era of rational drug design.
Advancements in experimental technologies delivered atomic and even sub-Ångstrom insights into complex protein structures, while predictive modelling, generative AI, and machine learning continued to redefine what was possible in drug design. At the same time, with tightening R&D budgets, the need to derisk early drug discovery programs through more rational design and to identify more potent, selective, and developable drug candidates proved more important than ever.
The event provided a valuable opportunity for peers across Structural Biology, Medicinal Chemistry, Computational Chemistry, Protein Engineering, Machine Learning, and related disciplines to stay at the forefront of innovation, benchmark approaches, and explore how to translate structural insights into better therapies.
Companies That Attended Include